From innovation to therapeutic care
Go faster for Sickle Cell Disease patients
INNOVHEM
A based-Genopole company founded on breakthrough innovation,
INNOVHEM is developing solutions that will both promote the development and optimization of use of treatments for the most common genetic disease over the world, sickle cell disease.
Our proposition
Specific Biomarkers
We are developing specific biomarkers for Red Blood Cell diseases that will improve the development of effective treatments and accompany these treatments in patients to optimize their care.
Fetal Hemoglobin per Red Blood Cell
- Related to the pathophysilogy of Sickle Cell Disease
- Accurate
A new method to dose intra-vascular hemolysis
- Direct
- Accurate
The Team
A leadership on Sickle Cell Disease
Laura Bencheikh
Project Manager